Aromatase inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone
responsive early carcinoma of the breast as demonstrated in a number of large international …

Aromatase inhibitors (AIS) are commonly used as adjuvant treatment in postmenopausal
women with hormone receptor–positive early breast cancer. With both steroidal and …

Aromatase inhibitors are the gold standard in the treatment of hormone receptor‐positive
breast cancer, but lead to an arthralgia syndrome which is implicated in 13–22% of …

It is well documented that the aromatase inhibitors (AIs) are superior to tamoxifen as
adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive …

Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+)
breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy …

Recent clinical trials have demonstrated that aromatase inhibitors (AIs) are slightly more
effective than tamoxifen at reducing breast cancer recurrences. However, breast cancer …

Background Although aromatase inhibitors have proven to be an effective treatment of
hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor …

Purpose: Aromatase inhibitors (AIs) are routinely used as first-line adjuvant treatment of
breast cancer in postmenopausal women with hormone receptor positive tumors. The …

Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase
inhibitor therapies in patients with breast cancer. A systematic review using network meta …

For the upfront adjuvant therapy of postmenopausal estrogen receptor–positive breast
cancer, the third-generation aromatase inhibitors (AIS) have shown a more favourable …